TONYEIGHT
Recent PBYI News
- Puma Biotechnology Reports First Quarter Financial Results • Business Wire • 05/02/2024 08:05:00 PM
- Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results • Business Wire • 04/18/2024 08:15:00 PM
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 09:30:00 PM
- Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer • Business Wire • 03/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:16:09 PM
- Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/29/2024 09:05:00 PM
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 02/27/2024 11:30:00 PM
- Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference • Business Wire • 02/22/2024 09:10:00 PM
- Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/15/2024 09:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 11:03:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 11:01:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 11:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 10:54:09 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:19:11 PM
- Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer • Business Wire • 02/13/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 08:54:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 02:00:45 PM
- Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference • Business Wire • 01/11/2024 09:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 09:41:48 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:38:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 12:03:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 12:00:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 11:42:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/04/2024 02:40:50 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM